AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Cue Biopharma, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00FVMPFP5
18.66▼ 0.23 (-1.22%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
18.89
Day's Range
18.04 – 19.35
52-Week Range
0.17 – 45.50
Volume
79.4K
Avg Volume
357.2K
Share Statistics
Shares Outstanding
Employees
29
Exchange
XNAS
Listed
2018-01-02
Share count as of August 12, 2026

Cue Biopharma, Inc. (CUE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cue Biopharma, Inc. (CUE)
What is Cue Biopharma, Inc.'s Market Cap?
Cue Biopharma, Inc.'s Market Cap is $135.6M, based on as-reported figures from SEC (XBRL) filings.
What is Cue Biopharma, Inc.'s Price / Sales?
Cue Biopharma, Inc.'s Price / Sales is 3.6×, based on as-reported figures from SEC (XBRL) filings.
What is Cue Biopharma, Inc.'s Revenue (TTM)?
Cue Biopharma, Inc.'s Revenue (TTM) is $37.7M, based on as-reported figures from SEC (XBRL) filings.
What is Cue Biopharma, Inc.'s Net Income (TTM)?
Cue Biopharma, Inc.'s Net Income (TTM) is -$164.1M, based on as-reported figures from SEC (XBRL) filings.
What is Cue Biopharma, Inc.'s EBITDA?
Cue Biopharma, Inc.'s EBITDA is -$97.3M, based on as-reported figures from SEC (XBRL) filings.
What is Cue Biopharma, Inc.'s Diluted EPS (TTM)?
Cue Biopharma, Inc.'s Diluted EPS (TTM) is -22.59, based on as-reported figures from SEC (XBRL) filings.
What is Cue Biopharma, Inc.'s EBITDA Margin?
Cue Biopharma, Inc.'s EBITDA Margin is -258.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CUEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue
YoY growth+166.7%+1250.6%+1292.3%-35.6%
Operating expenses:
General and administrative
Research and development
Gain on lease termination——
Total operating expenses
% of revenue1213.3%194.1%91.0%453.4%
Loss from operations
% of revenue-1113.3%-94.1%9.0%-353.4%
Other income (expense):
Interest income
Interest expense
Loss on issuance of liability-classified warrants and related issuance costs———
Changes in fair value of financial instruments———
Total other income (expense), net
Net loss
% of revenue-1943.2%-91.1%7.2%-346.6%
Net loss per common share, basic
Net loss per common share, diluted